Expression of miR-409-3p in ovarian serous carcinoma and its effect on biological behaviors of HO-8910 cells

Jing ZHU; Longhui ZHANG; Rongkai XIE

doi:10.16016/j.1000-5404.202007047

您当前的位置：

首页 >

文章列表页 >

Expression of miR-409-3p in ovarian serous carcinoma and its effect on biological behaviors of HO-8910 cells

Clinical Medicine | 更新时间：2026-01-09

- Expression of miR-409-3p in ovarian serous carcinoma and its effect on biological behaviors of HO-8910 cells
- Journal of Third Military Medical University Vol. 42, Issue 22, Pages: 2244-2250(2020)
- 作者机构：
  
  400037 重庆，陆军军医大学(第三军医大学)第二附属医院妇产科
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202007047
  CLC： R394.2;R730.23;R737.31
- Received：07 July 2020，
  
  Revised：2020-09-06，
  
  Published：30 November 2020
- 稿件说明：
移动端阅览
Jing ZHU, Longhui ZHANG, Rongkai XIE. Expression of miR-409-3p in ovarian serous carcinoma and its effect on biological behaviors of HO-8910 cells[J]. Journal of Third Military Medical University, 2020, 42(22): 2244-2250.
DOI：

Jing ZHU, Longhui ZHANG, Rongkai XIE. Expression of miR-409-3p in ovarian serous carcinoma and its effect on biological behaviors of HO-8910 cells[J]. Journal of Third Military Medical University, 2020, 42(22): 2244-2250. DOI： 10.16016/j.1000-5404.202007047.

摘要

目的

探讨微小RNA-409-3p (microRNA-409-3p或miR-409-3p)在卵巢浆液性癌组织中的表达和临床意义以及对HO-8910细胞生物学特性的影响。

方法

选取2014年本院手术治疗的40例卵巢浆液性癌组织和20例正常卵巢组织，采用RT-qPCR法检测miR-409-3p在各组织中的表达，分析其与患者临床病理参数之间的关系。进一步分析miR-409-3p在人卵巢浆液性癌细胞HO-8910、SKOV3和卵巢表皮细胞IOSE80中的表达差异；对人卵巢浆液性癌HO-8910细胞进行瞬时转染miR-409-3p模拟物(mimics)，分别采用CCK8细胞增殖实验、流式细胞术和Transwall侵袭实验检测过表达miR-409-3p对HO-8910细胞增殖、凋亡和侵袭能力的影响。

结果

miR-409-3p在卵巢浆液性癌组织中的表达较卵巢正常组织显著降低(

0.001)，低表达的miR-409-3p与患者国际妇产科联合会(international federation of gynecology and obstetrics

FIGO)分期和大网膜转移存在显著相关性(

0.05)，与患者年龄、组织学分级和CA125指标无显著相关(

0.05)；miR-409-3p低表达组的总生存期显著低于高表达组(

0.05)。与IOSE80细胞相比，miR-409-3p在HO-8910和SKOV3细胞中表达减少。与空白对照组和阴性对照组相比，转染miR-409-3p mimics后HO-8910细胞增殖和侵袭能力明显降低，细胞凋亡比例明显增加(

0.05)。

结论

miR-409-3p在卵巢浆液性癌组织和细胞中呈低表达状态，其表达水平与患者FIGO分期、大网膜转移和总生存期有关，过表达miR-409-3p显著抑制HO-8910细胞的增殖和侵袭能力，促进细胞凋亡。

Abstract

Objective

To investigate the expression of miR-409-3p in ovarian serous carcinoma and its correlation with the clinicopathological characteristics of the patients and observe the effect of miR-409-3p overexpression on the proliferation

invasion and apoptosis of HO-8910 cells.

Methods

We collected 40 tissue specimens of ovarian serous carcinomas and 20 normal ovarian tissues from patients undergoing surgeries for ovarian serous carcinoma in our hospital between January

2014 and December

2014. We examined the expression of miR-409-3p in the tissue specimens using RT-qPCR and explored the correlation of miR-409-3p with the clinicopathological parameters of the patients. We also detected the expression of miR-409-3p in 2 ovarian serous carcinoma cell lines (HO-8910 and SKOV3) and a human ovarian epithelial cell line (IOSE80). The effects of transient transfection with miR-409-3p mimics on the proliferation

apoptosis and invasion of HO-8910 cells were observed using CCK8 assay

flow cytometry and Transwell invasion assay

respectively.

Results

The expression of miR-409-3p was significantly lower in ovarian serous carcinoma tissues than in normal ovarian tissues (

0.001) and showed significant correlations with the FIGO stage (Ⅲ/Ⅳ) and omental metastasis of the tumor (

0.05)

but not with the patients'age

histological grade or CA125 level (

0.05). The patients with low miR-409-3p expressions had significantly shorter overall survival than those with high miR-409-3p expression levels (

0.05). The expression of miR-409-3p was also significantly lower in HO-8910 and SKOV3 cells than in IOSE80 cells

and overexpression of miR-409-3p significantly suppressed the proliferation and invasion and promoted the apoptosis of HO-8910 cells (

0.05).

Conclusion

miR-409-3p is lowly expressed in ovarian serous carcinoma and its expression level is significantly correlated with the FIGO stage

omental metastasis and overall survival of the patients. Overexpression of miR-409-3p inhibits the proliferation and invasion and promotes apoptosis of HO-8910 cells

suggesting the value of miR-409-3p as a potential prognostic indicator and a therapeutic target for ovarian serous carcinomas.

关键词

Keywords

references

HATANO Y, HATANO K, TAMADA M, et al . A comprehensive review of ovarian serous carcinoma[J ] . Adv Anat Pathol, 2019, 26(5): 329-339. DOI: 10.1097/pap.0000000000000243.

WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41: 3-14. DOI: 10.1016/j.bpobgyn.2016.08.006.

CAI Y, YU X, HU S, et al . A brief review on the mechanisms of miRNA regulation[J ] . Genom Proteom Bioinf, 2009, 7(4): 147-154. DOI: 10.1016/s1672-0229(08)60044-3.

MA Z, LI Y, XU J, et al . MicroRNA-409-3p regulates cell invasion and metastasis by targeting ZEB1 in breast cancer[J ] . IUBMB Life, 2016, 68(5): 394-402. DOI: 10.1002/iub.1494.

ZHENG B, LIANG L, HUANG S, et al . MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers[J ] . Oncogene, 2012, 31(42): 4509-4516. DOI: 10.1038/onc.2011.581.

SHUKLA V, VARGHESE V K, KABEKKODU S P, et al . Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer[J ] . Gynecol Oncol, 2019, 155(1): 135-143. DOI: 10.1016/j.ygyno.2019.08.012.

TAN S, SHI H, BA M, et al . miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy[J ] . Int J Mol Med, 2016, 37(4): 1030-1038. DOI: 10.3892/ijmm.2016.2492.

XU X L, ZHU Y, LIANG Z, et al . C-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling[J ] . Cell Death Dis, 2016, 7: e2088. DOI: 10.1038/cddis.2015.274.

VISHNOI A, RANI S. MiRNA biogenesis and regulation of diseases: an overview[J]. Methods Mol Biol, 2017, 1509: 1-10. DOI: 10.1007/978-1-4939-6524-3_1.

NASSAR F J, NASR R, TALHOUK R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction[J]. Pharmacol Ther, 2017, 172: 34-49. DOI: 10.1016/j.pharmthera.2016.11.012.

QADIR M I, FAHEEM A. miRNA: a diagnostic and therapeutic tool for pancreatic cancer[J]. Crit Rev Eukaryot Gene Expr, 2017, 27(3): 197-204. DOI: 10.1615/critreveukaryotgeneexpr.2017019494.

IORIO M V, CROCE C M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med, 2012, 4(3): 143-159. DOI: 10.1002/emmm.201100209.

汪春年, 李征, 方建晨, 等.卵巢浆液性腺癌血清miRNA差异表达及其临床意义[J].浙江实用医学, 2015, 20(6): 406-408, 412.

WANG C N, LI Z, FANG J C, et al . Differential expression of serum miRNA in ovarian serous adenocarcinoma and its clinical significance[J ] . Zhejiang Pract Med, 2015, 20(6): 406-408, 412.

WILCZYŃSKI M, ŻYTKO E, DANIELSKA J, et al . Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer[J ] . Arch Gynecol Obstet, 2018, 297(3): 741-748. DOI: 10.1007/s00404-018-4660-5.

ZHOU J, GONG G, TAN H, et al . Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma[J ] . Oncol Rep, 2015, 33(6): 2915-2923. DOI: 10.3892/or.2015.3937.

王莎莎, 张莹, 陶林, 等.基于TCGA数据的卵巢浆液性癌预后相关miRNAs筛选[J].临床与实验病理学杂志, 2018, 34(12): 1311-1314.

WANG S S, ZHANG Y, TAO L, et al . Scre ening of prognosis-related miRNAs in serous ovarian carcinoma based on TCGA database[J ] . Chin J Clin Exp Pathol, 2018, 34(12): 1311-1314.

冯金鑫, 张相良. miR-409-3p与胃癌关系的研究进展[J].消化肿瘤杂志(电子版), 2018, 10(2): 75-78. DOI:10.3969/j.issn.1673-534X.2015.03.003.

FENG J X, ZHANG X L. Research progress of microRNA miR-409-3p in gastric cancer[J]. J Dig Oncol (Electron Version), 2018, 10(2): 75-78. DOI:10.3969/j.issn.1673-534X.2015.03.003.

ZHANG G, LIU Z, XU H, et al . miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1[J ] . Biochem Biophys Res Commun, 2016, 469(2): 189-195. DOI: 10.1016/j.bbrc.2015.11.099.

KIM Y W, KIM E Y, JEON D, et al . Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells[J ] . Drug Des Devel Ther, 2014, 8: 293-314. DOI: 10.2147/dddt.s51969.

[CHENG Y, BAN R W, LIU W, et al . MiRNA-409-3p enhances cisplatin-sensitivity of ovarian cancer cells by blocking the autophagy mediated by Fip200[J ] . Oncol Res, 2018.[Online ahead of print ] . DOI: 10.3727/096504017x15138991620238 http://dx.doi.org/10.3727/096504017x15138991620238 ..

ZHANG S, ZHANG X, FU X, et al . Identification of common differentially-expressed miRNAs in ovarian cancer cells and their exosomes compared with normal ovarian surface epithelial cell cells[J ] . Oncol Lett, 2018, 16(2): 2391-2401. DOI: 10.3892/ol.2018.8954.

ZHANG J, HOU W, JIA J, et al . MiR-409-3p regulates cell proliferation and tumor growth by targeting E74-like factor 2 in osteosarcoma[J ] . FEBS Open Bio, 2017, 7(3): 348-357. DOI: 10.1002/2211-5463.12177.

CHEN H, DAI J. miR-409-3p suppresses the proliferation, invasion and migration of tongue squamous cell carcinoma via targeting RDX[J]. Oncol Lett, 2018, 16(1): 543-551. DOI: 10.3892/ol.2018.8687.

WU L, ZHANG Y, HUANG Z, et al . MiR-409-3p inhibits cell proliferation and invasion of osteosarcoma by targeting zinc-finger E-box-binding homeobox-1[J ] . Front Pharmacol, 2019, 10: 137. DOI: 10.3389/fphar.2019.00137.

时伟丽, 王鑫, 廖世秀.人类微小RNA-409-3p靶基因预测及生物信息学分析[J].中国优生与遗传杂志, 2017, 25(11): 18-19, 66.

SHI W L, WANG X, LIAO S X. Prediction of target genes of Homo sapiens miroRNA-409-3p and bioinformatics analysis[J]. Chin J Birth Heal Hered, 2017, 25(11): 18-19, 66.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰